Related Experiment Video
Updated: Jul 31, 2025
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
Clustering of Cardiac Transcriptome Profiles Reveals Unique: Subgroups of Dilated Cardiomyopathy Patients
Job A J Verdonschot1,2, Ping Wang1, Kasper W J Derks1
1Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands.
Insights
Dilated cardiomyopathy patient subgroups were identified using cardiac transcriptome data. This approach reveals distinct pathophysiological pathways for personalized treatment strategies in heart disease.
Area of Science:
- Cardiology
- Genomics
- Systems Biology
Background:
- Dilated cardiomyopathy presents diverse genetic and environmental causes.
- Current treatments often lack personalization due to disease heterogeneity.
- The cardiac transcriptome offers insights into individual patient pathophysiology.
Purpose of the Study:
- To identify homogeneous patient subgroups in dilated cardiomyopathy.
- To leverage genotype, phenotype, and transcriptome data for subtyping.
- To uncover distinct pathophysiological pathways for targeted therapies.
Main Methods:
- Clustering techniques applied to multi-omic data (genotype, phenotype, transcriptome).
- Analysis of early- and end-stage dilated cardiomyopathy patient cohorts.
- Identification of molecular pathways differentiating subgroups.
Main Results:
- Homogeneous patient subgroups were identified based on shared pathophysiology.
- Distinct subgroups emerged related to protein quality control, metabolism, cardiomyocyte function, and inflammation.
- Specific molecular pathways were associated with different patient clusters.
Conclusions:
- Subgrouping dilated cardiomyopathy patients based on molecular profiles is feasible.
- Identified pathways offer potential for guiding future personalized treatment.
- This approach can lead to individualized patient care strategies for heart conditions.
Abstract:
Dilated cardiomyopathy is a heterogeneous disease characterized by multiple genetic and environmental etiologies. The majority of patients are treated the same despite these differences. The cardiac transcriptome provides information on the patient's pathophysiology, which allows targeted therapy. Using clustering techniques on data from the genotype, phenotype, and cardiac transcriptome of patients with early- and end-stage dilated cardiomyopathy, more homogeneous patient subgroups are identified based on shared underlying pathophysiology. Distinct patient subgroups are identified based on differences in protein quality control, cardiac metabolism, cardiomyocyte function, and inflammatory pathways. The identified pathways have the potential to guide future treatment and individualize patient care.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:25Cardiomyopathy I: Introduction and Classification
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy